医药赛道迅速蹿红 主题基金迎上报高峰

Group 1 - The innovative drug sector has seen a significant recovery this year, becoming a popular investment area in the secondary market, with public funds reporting a peak in pharmaceutical-themed fund applications in the second quarter, totaling around 30 products, comparable to the total number for the entire year of 2024 [1][2] - Public funds heavily invested in innovative drug stocks have achieved returns exceeding 80% this year, leading to substantial inflows into related thematic index funds, such as the Huatai-PineBridge ETF, which saw net inflows of over 4.4 billion yuan, increasing its scale from 653 million yuan to 6.489 billion yuan [2] - The investment sentiment in the innovative drug sector is rising, with many institutional investors showing strong interest, and the approval speed for pharmaceutical-themed funds is accelerating to meet market demand [4][5] Group 2 - The innovative drug sector's valuation is under discussion, with some experts suggesting that while the current valuation is not low, it has not yet reached a bubble stage, indicating potential for further increases as more drug pipelines advance to late-stage clinical trials [4][5][6] - The investment opportunities in the innovative drug sector are seen as a result of ten years of research and development, with expectations for significant business development contributions and improved financial reports in the coming years [7] - Different fund companies are adopting varied strategies for product layout, with a focus on active management products in the innovative drug sector, which may offer better opportunities for excess returns compared to passive products [8]